{"id":"W2473420009","doi":"10.1200/jco.2014.32.15_suppl.3514","title":"Phase I study of the selective BRAF<sup>V600 </sup>inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced <i>BRAF</i>-mutant colorectal cancer.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Cetuximab; Medicine; Tolerability; Pharmacology; Vomiting; Internal medicine; Oncology; Colorectal cancer; Cancer; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009110065,0.00151109,0.001907392,0.0004087143,0.0003494123,0.0008638581,0.000865576,0.0009637434,0.002985256],"category_scores_gemma":[0.0005199351,0.0007431014,0.001073256,0.0003654348,0.0008667442,0.0007721261,0.0003504432,0.002622775,0.0006884371],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001139647,"about_ca_system_score_gemma":0.001681395,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001674438,"about_ca_topic_score_gemma":0.003990898,"domain_scores_codex":[0.9997118,0.0001064869,0.00001471841,0.00005891794,0.00002786443,0.0000801475],"domain_scores_gemma":[0.9994449,0.00006448667,0.0001100623,0.00003858148,0.00003152555,0.0003103267],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7052279,0.1006203,0.007697386,0.0007811249,0.001432293,0.0003323172,0.0003447173,0.003460502,0.08733865,0.0002575097,0.003235338,0.08927193],"study_design_scores_gemma":[0.2742838,0.701139,0.0115886,0.00002604633,0.0005459561,0.0003324932,0.0000751061,0.0009462,0.008254906,0.0001054241,0.002674426,0.00002817011],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9947796,0.001186527,0.0004112152,0.0002270606,0.00007252651,0.001451196,0.0005046667,0.00007444331,0.001292795],"genre_scores_gemma":[0.9927446,0.001186067,0.001040096,0.0003546249,0.00008848364,0.001159124,0.001295615,0.00002180733,0.002109589],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002985256,"threshold_uncertainty_score":0.009986699,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03056508449280592,"score_gpt":0.3714473643200866,"score_spread":0.3408822798272806,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}